Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript